ARCH Venture Capital, a venture capital firm, led a $50m Series A round in Vilya, a biotechnology company. Vilya’s computational design platform leverages advanced machine learning and other computational approaches to explore an exponentially larger chemical space and design desired drug properties. These capabilities position the company to precisely target disease biology.